SOCS3 and SOCS5 mRNA expressions may predict initial steroid response in nephrotic syndrome children

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 719-728

  Ostalska Nowicka, Danuta ^a   Smiech, Magdalena ^a   Jaroniec, Malgorzata ^a   Zaorska, Katarzyna ^a   Zawierucha, Piotr ^a   Szaflarski, Witold ^a   Malińska, Agnieszka ^a   Nowicki, Michal ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Children; Jak stat signaling pathway; Leukocytes; Nephrotic syndrome; Resistance to steroids

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 20; INTERLEUKIN 6; JANUS KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 5; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE PRODUCT; GLOMERULUS FILTRATION RATE; HUMAN; JAK1 GENE; JAK2 GENE; JAK3 GENE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOCS1 GENE; SOCS2 GENE; SOCS3 GENE; SOCS4 GENE; SOCS5 GENE; STAT1 GENE; STAT2 GENE; STAT6 GENE; TYK2 GENE;

EID: 84856799525     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0096     Document Type: Article

References (24)

1. Schönenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant. 2011;26:18-24.
2. Ostalska-Nowicka D, Nowicki M, Kondraciuk B, Partyka M, Samulak D, Witt M. Expression of galectin-3 in nephrotic syndrome glomerulopathies in children. Folia Histochem Cytobiol. 2009;47:315-322.
3. Luczynski W, Stasiak-Barmuta A, Juchniewicz A et al. The mRNA expression of pro- and anti-inflammatory cytokines in T regulatory cells in children with type 1 diabetes. Folia Histochem Cytobiol. 2010;48:93-100.
4. Ben Ameur R, Molina L, Bolvin C et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant. 2010;25:2866-2875.
5. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26:28-35.
6. Kucejko W, Chyczewska E, Naumnik W, Ossolinska M. Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis. Folia Histochem Cytobiol. 2009;47:225-230.
7. Yang JW, Choi SO, Kim BR et al. Nephrotic syndrome associated with invasive mole: a case report. Nephrol Dial Transplant. 2010;25:2023-2026.
8. Rolleman EJ, Weening J, Betjes MG. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant. 2009;24:2002-2003.
9. Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2010;25:124-129.
10. Wang J, Ouyang C, Chen X, Fu B, Lu Y, Hong Q. Effect of Jak2 kinase inhibition on Stat1 and Stat3 activation and apoptosis of tubular epithelial cells induced by ATP depletion/ /recovery. J Nephrol. 2008;21:919-923.
11. Camici M. The Nephrotic Syndrome is an immunoinflammatory disorder. Med Hypotheses. 2007;68:900-905.
12. Cisowski J, Zarebski A, Koj A. IL-1-mediated inhibition of IL-6-induced STAT3 activation is modulated by IL-4, MAP kinase inhibitors and redox state of HepG2 cells. Folia Histochem Cytobiol. 2002;40:341-345.
13. Li R, Yang N, Zhang L et al. Inhibition of JaK/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol. 2007;27:580-589.
14. Nakajima H, Takenaka M, Kaimori JY et al. Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin. J Am Soc Nephrol. 2004;15:276-285.
15. Melvin T, Bennett W. Management of nephrotic syndrome in childhood. Drugs. 1991;42:30-51.
16. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf- Vereijken PW, Wetzels JF. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2010;25:129-136.
17. Clark AG, Barratt TM. Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE (eds). Pediatric nephrology. Baltimore, Lippincott Williams & Wilkins, 1998:731-747.
18. van Stralen KJ, Tizard EJ, Jager KJ et al. Determinants of eGFR at start of renal replacement therapy in paediatric patients. Nephrol Dial Transplant. 2010;25:3325-3332.
19. Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 2009;390:1-4.
20. Armitage P, Gehan EA. Statistical methods for the identification and use of prognostic factors. Int J Cancer. 1974;13:16-36.
21. Yasukawa H, Ohishi M, Mori H et al. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nature Immunol. 2003;4:551-556.
22. Nicholson SE, Willson TA, Farley A et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-385.
23. Magrangeas F, Apiou F, Denis S, Weidle U, Jacques Y, Minvielle S. Cloning and expression of CIS6, chromosome assignment to 3p22 and 2p21 by in situ hybridization. Cytogenet Cell Genet. 2000;88:78-81.
24. Seki Y, Hayashi K, Matsumoto A et al. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA. 2002;99:13003-13008.